Rigel Pharmaceuticals (RIGL) Enterprise Value (2010 - 2026)

Rigel Pharmaceuticals' Enterprise Value history runs 17 years deep, the most recent figure standing at -$146.7 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 90.25% year-over-year to -$146.7 million; the TTM figure through Mar 2026 stood at -$146.7 million (down 90.25% YoY), while the FY2025 annual figure was -$155.0 million, down 100.4% from the prior year.
• Enterprise Value for Q1 2026 stood at -$146.7 million, up from -$155.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$49.1 million in Q2 2024, with the low at -$155.0 million in Q4 2025.
• The 5-year median for Enterprise Value is -$77.1 million (2025), against an average of -$84.7 million.
• Peak annual rise in Enterprise Value reached 53.42% in 2022, while the deepest fall reached 173.27% in 2022.
• Rigel Pharmaceuticals' Enterprise Value stood at -$58.2 million in 2022, then grew by 2.19% to -$56.9 million in 2023, then tumbled by 35.81% to -$77.3 million in 2024, then slumped by 100.4% to -$155.0 million in 2025, then grew by 5.34% to -$146.7 million in 2026.
• Business Quant data shows RIGL's Enterprise Value at -$146.7 million in Q1 2026, -$155.0 million in Q4 2025, and -$137.1 million in Q3 2025.